Company: BKYI
Filing Date: 2025-06-27
Form Type: DEF 14A
Source: 0001437749-25-021438
Chunk: 31

Company: BIO KEY INTERNATIONAL INC
Filing Date: 2025-06-27
Form: DEF 14A
Chunk 31
---
000 |     |              | 6,002 |     |       | 12,002 |
| Cameron Williams (5) |     |                | 6,000 |     |              | 7,002 |     |       | 13,002 |

| (1) | Mr. DePasquale and Kelvin Wong have been omitted from the above table because they do not receive any additional compensation for serving on our board of directors. |

| (2) | The aggregate fair value of the common stock issued was calculated based on the closing price of our common stock on the date of issuance in accordance with FASB ASC 718. |

| (3) | At December 31, 2024, Mr. Michel held options to purchase 36 shares of common stock and held 6,365 shares of restricted common stock. |

| (4) | At December 31, 2024, Mr. Alia held options to purchase 18 shares of common stock and held 6,365 shares of restricted common stock. |

| (5) | At December 31, 2024, Mr. Williams held 6,365 shares of restricted common stock. |

Narrative Disclosure to Director Compensation Table

During 2024, we had a policy to pay each non-employee director $3,000 per regular board meeting, and $1,000 per board committee meeting attended. Fees for attendance at regular board meetings held during each fiscal year are paid through the issuance of common stock or, at the option of the director, cash. No additional fees were paid for special meetings. All of our directors elected to receive payment in cash for the second and third regular board meetings in 2024. Compensation for all other regular board and board committee meetings was paid in stock. All directors will be indemnified by us for actions associated with being a director to the fullest extent permitted under Delaware law. We reimburse each of our non-employee directors for their reasonable expenses incurred in connection with attending meetings of the board of directors and related committees.

<div align='center'>19</div>

PROPOSAL 2: RATIFICATION OF THE SELECTION OF BUSH & ASSOCIATES CPA LLC AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025

General

The audit committee has appointed Bush & Associates CPA LLC (“Bush & Associates”) to audit and report on the consolidated financial statements of the Company and its subsidiaries for the fiscal year